Vetoquinol (VETO) - Total Liabilities
Based on the latest financial reports, Vetoquinol (VETO) has total liabilities worth €158.29 Million EUR (≈ $185.05 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VETO net assets growth trend to track the company's year-over-year net asset growth rate.
Vetoquinol - Total Liabilities Trend (2004–2024)
This chart illustrates how Vetoquinol's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Vetoquinol generate to measure how efficiently the company converts operating cash flow to free cash.
Vetoquinol Competitors by Total Liabilities
The table below lists competitors of Vetoquinol ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lintes Technology Co Ltd
TW:6715
|
Taiwan | NT$888.20 Million |
|
Shenzhen Strongteam Decoration Engineering Co Ltd
SHE:002989
|
China | CN¥737.49 Million |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥735.96 Million |
|
Shenzhen WOTE Advanced Materials Co Ltd
SHE:002886
|
China | CN¥1.83 Billion |
|
AMAG Austria Metall AG
VI:AMAG
|
Austria | €924.93 Million |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
China | CN¥275.13 Million |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
China | CN¥8.94 Billion |
|
Pearl Global Industries Limited
NSE:PGIL
|
India | Rs18.07 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Vetoquinol's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vetoquinol (VETO) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vetoquinol's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vetoquinol (2004–2024)
The table below shows the annual total liabilities of Vetoquinol from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €168.20 Million ≈ $196.64 Million |
+1.86% |
| 2023-12-31 | €165.12 Million ≈ $193.04 Million |
-1.23% |
| 2022-12-31 | €167.19 Million ≈ $195.46 Million |
-8.75% |
| 2021-12-31 | €183.21 Million ≈ $214.19 Million |
-33.20% |
| 2020-12-31 | €274.26 Million ≈ $320.64 Million |
+118.56% |
| 2019-12-31 | €125.49 Million ≈ $146.71 Million |
+22.43% |
| 2018-12-31 | €102.50 Million ≈ $119.83 Million |
-5.31% |
| 2017-12-31 | €108.24 Million ≈ $126.55 Million |
-11.78% |
| 2016-12-31 | €122.70 Million ≈ $143.45 Million |
-0.23% |
| 2015-12-31 | €122.98 Million ≈ $143.78 Million |
-18.54% |
| 2014-12-31 | €150.97 Million ≈ $176.50 Million |
+30.28% |
| 2013-12-31 | €115.88 Million ≈ $135.47 Million |
-9.77% |
| 2012-12-31 | €128.43 Million ≈ $150.15 Million |
+20.00% |
| 2011-12-31 | €107.02 Million ≈ $125.12 Million |
-14.50% |
| 2010-12-31 | €125.18 Million ≈ $146.34 Million |
-2.75% |
| 2009-12-31 | €128.72 Million ≈ $150.49 Million |
+29.53% |
| 2008-12-31 | €99.38 Million ≈ $116.18 Million |
-1.15% |
| 2007-12-31 | €100.53 Million ≈ $117.53 Million |
+1.06% |
| 2006-12-31 | €99.47 Million ≈ $116.30 Million |
-11.89% |
| 2005-12-31 | €112.90 Million ≈ $131.99 Million |
+6.93% |
| 2004-12-31 | €105.58 Million ≈ $123.44 Million |
-- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more